Evidence map›Paper›PMID 26693063›Full record

ArticleAmerican journal of cancer research2015

Discovery and validation of potential bacterial biomarkers for lung cancer.

Xinmin Yan, Mingxia Yang, Juan Liu, Ruichen Gao, Jihong Hu, Jiong Li, Lijun Zhang, Yujia Shi, Hongrong Guo, Jinluo Cheng and 4 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04079400 (Microbiome in Patients With Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases), which is not on this map. Cited by 227 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 6 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04079400 completednot on this mapstarted 2016, after this paper: background citation

Microbiome in Patients With Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases (NTM-PD), Lung Cancer and Hemoptysis

Typeobservational_patient_registrySponsorGachon University Gil Medical CenterRan2016 to 2019Enrolled43ConditionsTuberculosis, Pulmonary, Non-Tuberculous Mycobacterial Pneumonia, Lung Cancer, Hemoptysis
3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 6 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  16. Article
  17. Multi-site screening forFrontiers in cellular and infection microbiology · 2026
    Article
  18. Article
  19. Review
  20. Article

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xinmin YanChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Mingxia YangChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Juan LiuChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Ruichen GaoChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Jihong HuChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Jiong LiSchool of Dentistry and Jonsson Comprehensive Cancer Center, University of California Los Angeles, CA 90095, USA.
Lijun ZhangDavid Geffen School of Medicine, University of California Los Angeles, CA 90095, USA.
Yujia ShiChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Hongrong GuoChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Jinluo ChengChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Miriam RaziSchool of Dentistry and Jonsson Comprehensive Cancer Center, University of California Los Angeles, CA 90095, USA.
Shen PangDavid Geffen School of Medicine, University of California Los Angeles, CA 90095, USA.
Xiaowei YuChangzhou Second People's Hospital, Nanjing Medical University Changzhou, 213003, China.
Shen HuSchool of Dentistry and Jonsson Comprehensive Cancer Center, University of California Los Angeles, CA 90095, USA.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbes are residents in a number of body sites, including the oral and nasal cavities, which are connected to the lung via the pharynx. The associations between oral diseases and increased risk of lung cancer have been reported in previous prospective studies. In this study, we measured variations of salivary microbiota and evaluated their potential association with lung cancer, including squamous cell carcinoma (SCC) and adenocarcinoma (AC). A three-phase study was performed: First, we investigated the salivary microbiota from 20 lung cancer patients (10 SCC and 10 AC) and control subjects (n=10) using a deep sequencing analysis. Salivary Capnocytophaga, Selenomonas, Veillonella and Neisseria were found to be significantly altered in patients with SCC and AC when compared to that in control subjects. Second, we confirmed the significant changes of Capnocytophaga, Veillonella and Neisseria in the same lung cancer patients using quantitative PCR (qPCR). Finally, these bacterial species were further validated on new patient/control cohorts (n=56) with qPCR. The combination of two bacterial biomarkers, Capnocytophaga and Veillonella, yielded a receiver operating characteristic (ROC) value of 0.86 with an 84.6% sensitivity and 86.7% specificity in distinguishing patients with SCC from control subjects and a ROC value of 0.80 with a 78.6% sensitivity and 80.0% specificity in distinguishing patients with AC from control subjects. In conclusion, we have for the first time demonstrated the association of saliva microbiota with lung cancer. Particularly, the combination of the 16S sequencing discovery with qPCR validation studies revealed that the levels of Capnocytophaga and Veillonella were significantly higher in the saliva from lung cancer patients, which may serve as potential biomarkers for the disease detection/classification.

Indexed as

16S rDNA sequencingCapnocytophagaLung cancersaliva microbiotaVeillonella

Identifiers

PMID26693063
PMCPMC4656734
OpenAlexW2202883403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.